- Request Lead Time
- In stock and ready for quick dispatch
- Usually dispatched within 2-3 weeks
Shipping Destination:United States
Shipping charges:Freight/Packing: $34.00
Need Help?Ask a Question Support@biorbyt.com
Skip to the end of the images gallery
Catalog Number: orb61177
|Tested applications||HPLC, NMR|
|Alternative Names||(click to expand) Recentin|
|Storage||2 years -20 °C as powder |
2 weeks 4 °C in DMSO
6 months -80 °C in DMSO
|Note||For research use only.|
|PubChem CID||CID 9933475|
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. Cediranib is currently being evaluated in a phase II clinical trial for the treatment of advanced solid tumors.
|Application Notes||In vitro: Cediranib inhibits VEGF-stimulated proliferation with IC50 of 0.4 nM.Cediranib suppresses PDGF-AA with IC50 of 0.04 μM in MG63 cell lines.Cediranib has been shown to block Flt1-associated kinase with IC50 of 5 nM and VEGF-C and VEGF-D receptor Flt-4 with IC50 less than 3 nM.In addition, the IC50 values for inhibition of c-Kit and PDGFRβ tyrosine kinase are 2 nM and 5 nM respectively.Furthermore, no inhibition of enzyme activity is observed when 10 μM Cediranib is assayed with 100 μM ATP against AMPK, Chk1 Akt/PKB and others.Micromolar concentrations of Cediranib are needed to prevent tumor cell proliferation in vitro.
In vivo: Cediranib even suppresses tubule sprouting at subnanomolar concentrations and inhibits VEGF-induced angiogenesis.Cediranib causes hypertrophy in bone growth plate and prevents luteal development in ovary.These are physiological processes that are dependent upon angiogenesis.Cediranib shows broad spectrum activity in human tumor models at doses that are well tolerated.Besides, Cediranib causes regression of vascular tissues in human lung tumor xenografts.
Write Your Own Review